1,439
Views
14
CrossRef citations to date
0
Altmetric
Research Paper

A seed motif for target RNA capture enables efficient immune defence by a type III-B CRISPR-Cas system

, , , , , , , ORCID Icon & ORCID Icon show all
Pages 1166-1178 | Received 21 Feb 2019, Accepted 06 May 2019, Published online: 26 May 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Mohamed Nasef, Sarah A. Khweis & Jack A. Dunkle. (2022) The effect of crRNA–target mismatches on cOA-mediated interference by a type III-A CRISPR-Cas system. RNA Biology 19:1, pages 1293-1304.
Read now
Isabelle Anna Zink, Thomas Fouqueau, Gabriel Tarrason Risa, Finn Werner, Buzz Baum, Udo Bläsi & Christa Schleper. (2021) Comparative CRISPR type III-based knockdown of essential genes in hyperthermophilic Sulfolobales and the evasion of lethal gene silencing. RNA Biology 18:3, pages 421-434.
Read now

Articles from other publishers (12)

Jinzhong Lin, Lauge Alfastsen, Yuvaraj Bhoobalan-Chitty & Xu Peng. (2023) Molecular basis for inhibition of type III-B CRISPR-Cas by an archaeal viral anti-CRISPR protein. Cell Host & Microbe 31:11, pages 1837-1849.e5.
Crossref
Luciano A. Marraffini. 2022. Crispr. Crispr 71 84 .
Yan Zhang, Jinzhong Lin, Xuhui Tian, Yuan Wang, Ruiliang Zhao, Chenwei Wu, Xiaoning Wang, Pengpeng Zhao, Xiaonan Bi, Zhenxiao Yu, Wenyuan Han, Nan Peng, Yun Xiang Liang & Qunxin She. (2022) Inactivation of Target RNA Cleavage of a III-B CRISPR-Cas System Induces Robust Autoimmunity in Saccharolobus islandicus. International Journal of Molecular Sciences 23:15, pages 8515.
Crossref
Pengjun Xia, Anirudha Dutta, Kushol Gupta, Mona Batish & Vijay Parashar. (2022) Structural basis of cyclic oligoadenylate binding to the transcription factor Csa3 outlines cross talk between type III and type I CRISPR systems. Journal of Biological Chemistry 298:2, pages 101591.
Crossref
Zulqurnain Khan, Zulfiqar Ali, Asif Ali Khan, Tahmina Sattar, Ali Zeshan, Tahira Saboor & Barkha Binyamin. 2022. The CRISPR/Cas Tool Kit for Genome Editing. The CRISPR/Cas Tool Kit for Genome Editing 29 52 .
Erika Wimmer, Isabelle Anna Zink & Christa Schleper. 2022. Archaea. Archaea 177 201 .
Zhenxiao Yu, Suping Jiang, Yuan Wang, Xuhui Tian, Pengpeng Zhao, Jianan Xu, Mingxia Feng & Qunxin She. (2020) CRISPR-Cas adaptive immune systems in Sulfolobales: genetic studies and molecular mechanisms. Science China Life Sciences 64:5, pages 678-696.
Crossref
Isabelle Anna Zink, Erika Wimmer & Christa Schleper. (2020) Heavily Armed Ancestors: CRISPR Immunity and Applications in Archaea with a Comparative Analysis of CRISPR Types in Sulfolobales. Biomolecules 10:11, pages 1523.
Crossref
Tina Y. Liu & Jennifer A. Doudna. (2020) Chemistry of Class 1 CRISPR-Cas effectors: Binding, editing, and regulation. Journal of Biological Chemistry 295:42, pages 14473-14487.
Crossref
Jinzhong Lin, Mingxia Feng, Heping Zhang & Qunxin She. (2020) Characterization of a novel type III CRISPR-Cas effector provides new insights into the allosteric activation and suppression of the Cas10 DNase. Cell Discovery 6:1.
Crossref
Xiaofeng Dai, Shuo Zhang & Kathia Zaleta-Rivera. (2019) RNA: interactions drive functionalities. Molecular Biology Reports 47:2, pages 1413-1434.
Crossref
Yingjun Li & Nan Peng. (2019) Endogenous CRISPR-Cas System-Based Genome Editing and Antimicrobials: Review and Prospects. Frontiers in Microbiology 10.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.